Free Trial

Asset Dedication LLC Sells 544 Shares of Eli Lilly and Company (NYSE:LLY)

Eli Lilly and Company logo with Medical background

Asset Dedication LLC lowered its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 10.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,506 shares of the company's stock after selling 544 shares during the period. Asset Dedication LLC's holdings in Eli Lilly and Company were worth $3,722,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Knightsbridge Asset Management LLC lifted its stake in shares of Eli Lilly and Company by 1.9% in the fourth quarter. Knightsbridge Asset Management LLC now owns 813 shares of the company's stock worth $628,000 after acquiring an additional 15 shares in the last quarter. LS Investment Advisors LLC grew its holdings in shares of Eli Lilly and Company by 1.7% during the first quarter. LS Investment Advisors LLC now owns 2,340 shares of the company's stock valued at $1,933,000 after purchasing an additional 40 shares during the last quarter. Prism Advisors Inc. bought a new position in shares of Eli Lilly and Company during the first quarter valued at approximately $207,000. CSM Advisors LLC grew its holdings in shares of Eli Lilly and Company by 30.6% during the fourth quarter. CSM Advisors LLC now owns 1,045 shares of the company's stock valued at $807,000 after purchasing an additional 245 shares during the last quarter. Finally, Proficio Capital Partners LLC grew its holdings in Eli Lilly and Company by 30.2% in the 4th quarter. Proficio Capital Partners LLC now owns 6,739 shares of the company's stock worth $5,202,000 after buying an additional 1,562 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Price Performance

NYSE:LLY traded up $17.16 on Wednesday, hitting $788.91. The company had a trading volume of 3,254,125 shares, compared to its average volume of 3,682,457. The stock has a market capitalization of $747.68 billion, a price-to-earnings ratio of 64.19, a PEG ratio of 1.12 and a beta of 0.40. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18. The firm has a 50 day moving average of $765.88 and a two-hundred day moving average of $799.99. Eli Lilly and Company has a 52 week low of $677.09 and a 52 week high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.64 by ($1.30). The business had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. Eli Lilly and Company's revenue was up 45.2% on a year-over-year basis. During the same period in the previous year, the business posted $2.58 EPS. On average, research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be given a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a dividend yield of 0.76%. The ex-dividend date is Friday, August 15th. Eli Lilly and Company's dividend payout ratio (DPR) is presently 48.82%.

Wall Street Analyst Weigh In

LLY has been the subject of a number of research analyst reports. HSBC downgraded Eli Lilly and Company from a "buy" rating to a "reduce" rating and cut their target price for the stock from $1,150.00 to $700.00 in a research report on Monday, April 28th. Erste Group Bank cut shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Thursday, June 5th. Hsbc Global Res cut shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research note on Monday, April 28th. UBS Group cut their target price on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. Finally, Wall Street Zen cut shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Saturday, June 28th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $1,012.56.

Check Out Our Latest Report on Eli Lilly and Company

Eli Lilly and Company Profile

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Featured Stories

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Should You Invest $1,000 in Eli Lilly and Company Right Now?

Before you consider Eli Lilly and Company, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.

While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Time to Cash Out? 5 Stocks to Drop Before Earnings
Watch Before Monday: Stocks to Load Up on Before Earnings
3 Hot Growth Stocks to Watch Right Now!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines